NCT05663034

Brief Summary

This study is a prospective two-arm, single blind randomized controlled trial design to compare the clinical effectiveness of telemedicine-delivered, 6-session, standardized cognitive behavioral therapy for insomnia (CBT-I) and mindfulness-based treatment for insomnia (MBTI) in treating insomnia symptoms and ameliorating depressive symptoms in persons with mild to moderate TBI and comorbid Post-Traumatic Stress Symptoms (PTSS) and insomnia symptoms in a 360 patients. Participants will undergo assessment (psychosocial questionnaires, neurocognitive testing, sleep monitoring) at baseline, at the end of treatment, and at 2-, 6- and 12-weeks post-treatment. The primary outcome is sleep as measured by the Insomnia Severity Index (ISI).

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
360

participants targeted

Target at P75+ for not_applicable

Timeline
4mo left

Started May 2024

Typical duration for not_applicable

Geographic Reach
1 country

5 active sites

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress86%
May 2024Sep 2026

First Submitted

Initial submission to the registry

December 14, 2022

Completed
9 days until next milestone

First Posted

Study publicly available on registry

December 23, 2022

Completed
1.4 years until next milestone

Study Start

First participant enrolled

May 10, 2024

Completed
2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 1, 2026

Completed
4 months until next milestone

Study Completion

Last participant's last visit for all outcomes

September 1, 2026

Expected
Last Updated

December 18, 2025

Status Verified

December 1, 2025

Enrollment Period

2 years

First QC Date

December 14, 2022

Last Update Submit

December 11, 2025

Conditions

Keywords

Traumatic Brain InjuryInsomniaPosttraumatic Stress SymptomsDepressionConcussionHead InjuryBrain InjuryCognitive Behavioral Therapy for InsomniaMindfulness-based Treatment for Insomnia

Outcome Measures

Primary Outcomes (1)

  • Change in Insomnia severity as assessed by the insomnia severity index (ISI)

    Insomnia symptoms and severity measured by insomnia severity index (ISI); score range: 0-28; Higher scores are associated with greater insomnia symptoms

    At the end of treatment, and 2-, 6- and 12-weeks post treatment

Study Arms (2)

Cognitive behavioral therapy for insomnia (CBT-I)

ACTIVE COMPARATOR

CBT-I treatment will involve a standardized 6-session blended intervention that combines cognitive and behavioral techniques. The core components include (1) education about sleep and insomnia, stimulus control (SC) and sleep restriction (SRT) (week 1); (2) sleep hygiene education (week 2); and (3) relaxation training, cognitive restructuring (to counter-arousal and address sleep-interfering cognitions), adherence monitoring, and adjusting the recommended sleep-wake schedule (weeks 3 through 6). The final session will also include a review of treatment content and relapse prevention. Common to all sessions is an initial review of participant diary data, charting progress, setting measurable goals, discussing adherence, and reinforcing learned skills.

Behavioral: Cognitive behavioral therapy for insomnia (CBT-I)

Mindfulness-based treatment for insomnia (MBTI)

ACTIVE COMPARATOR

MBTI treatment will involve a standardized 6-session intervention which integrates the mindfulness training and exercises from mindfulness-based stress reduction (MBSR) with behavioral strategies based on sleep restriction therapy and stimulus control delivered within the context of mindfulness principles. Mindfulness principles include: 1) increase awareness of the mental and physical states that promote sleep (i.e., sleepiness), 2) shift sleep-related metacognitions to reduce hyperarousal, and 3) promote a mindful stance to respond when symptoms of insomnia arise. An overview of the treatment program, sleep education, and an introduction to the principles of mindfulness meditation is given (week 1). Then a combination of mindfulness meditations, sleep restriction, and stimulus control is conducted (week 2-6).

Behavioral: Mindfulness-based treatment for insomnia (MBTI)

Interventions

A 6-week intervention that uses the principles and practices of mindfulness meditation along with behavioral strategies (stimulus control, sleep restriction therapy) to reduce symptoms of insomnia

Mindfulness-based treatment for insomnia (MBTI)

Standard of care for adults with chronic insomnia. 6-week program that uses behavioral techniques to decrease psychophysiological arousal and increase sleep propensity to deepen and consolidate sleep.

Cognitive behavioral therapy for insomnia (CBT-I)

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Current or former member of the uniform services
  • Meet the Veterans Affairs Medical Center (VAMC) Department of Defense (DoD) criteria for TBI;
  • Time duration since traumatic brain injury (TBI) injury \>90 days
  • Insomnia symptom duration \>90 days
  • Endorse insomnia symptoms (Insomnia Severity Index \[ISI\] score \> 10)
  • Display sufficient cognitive capacity to provide informed consent (Montreal Cognitive Assessment (MoCA) Z-score \> -2)
  • \>18 years of age
  • Access to and ability and to use computer.

You may not qualify if:

  • History of neurological diseases other than TBI and not attributable to TBI
  • Sleep apnea \[apnea hypopnea index (AHI) \>15; individuals with mild apnea (AHI \> 5 and \<15) will be informed, but allowed to participate\]. Participants who use a continuous positive airway pressure (CPAP) device for sleep apnea will be eligible for participation if they are below the apnea/hypopnea cutoff while using CPAP, are adherent to using the device (\> 4 hours/night 21/30 consecutive days) and agree to continue using the device during study participation.
  • Lastly, people using psychotropic medications may be included if they are on a stable dosage for the last three weeks prior to the study.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (5)

Intrepid Spirit Center - Eglin Air Force Base

Eglin Air Force Base, Florida, 32542, United States

RECRUITING

Naval School Explosive Ordance Disposal - Eglin Air Force Base

Eglin Air Force Base, Florida, 32542, United States

RECRUITING

Walter Reed National Medical Military Center

Bethesda, Maryland, 20814, United States

RECRUITING

Womack Army Medical Center

Fort Bragg, North Carolina, 28310, United States

RECRUITING

Madigan Army Medical Center

Fort Lewis, Washington, 98431, United States

RECRUITING

MeSH Terms

Conditions

Brain Injuries, TraumaticSleep Initiation and Maintenance DisordersDepressionMemory DisordersBrain ConcussionCraniocerebral TraumaBrain Injuries

Interventions

Cognitive Behavioral Therapy

Condition Hierarchy (Ancestors)

Brain DiseasesCentral Nervous System DiseasesNervous System DiseasesTrauma, Nervous SystemWounds and InjuriesSleep Disorders, IntrinsicDyssomniasSleep Wake DisordersMental DisordersBehavioral SymptomsBehaviorNeurobehavioral ManifestationsNeurologic ManifestationsSigns and SymptomsPathological Conditions, Signs and SymptomsHead Injuries, ClosedWounds, Nonpenetrating

Intervention Hierarchy (Ancestors)

Behavior TherapyPsychotherapyBehavioral Disciplines and Activities

Study Officials

  • Luis Buenaver, PhD

    Johns Hopkins School of Medicine

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Luis Buenaver, PHD

CONTACT

Elizabeth Wysocki, MS

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
INVESTIGATOR, OUTCOMES ASSESSOR
Masking Details
Investigators and outcome assessment technicians will remain blinded to treatment assignment.
Purpose
TREATMENT
Intervention Model
PARALLEL
Model Details: Prospective two-arm, single blind randomized controlled trial
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

December 14, 2022

First Posted

December 23, 2022

Study Start

May 10, 2024

Primary Completion

May 1, 2026

Study Completion (Estimated)

September 1, 2026

Last Updated

December 18, 2025

Record last verified: 2025-12

Locations